CORE--BIOCHEMISTRY AND BIOTECHNOLOGY

核心--生物化学与生物技术

• 批准号: 7467232
• 负责人: Robert C Young
• 金额: $ 55.32万
• 依托单位: FOX CHASE CANCER CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7467232
• 关键词: Area; Arts; Biochemical; Biochemistry; Biotechnology; Cancer Etiology; Collaborations; Complex; DNA Sequence Analysis; DNA biosynthesis; DNA chemical synthesis; Depth; Discipline; Disease; Doctor of Philosophy; Fluorescent Probes; Fox Chase Cancer Center; Funding; Gene Expression; Genes; Genetic Polymorphism; Grant; Human Resources; Investigation; Laboratories; Mass Spectrum Analysis; Modification; Mutation; Oligonucleotides; Participant; Peer Review; Peptides; Performance; Pharmaceutical Preparations; Polymerase Chain Reaction; Proteins; Proteomics; Quality Control; Regulation; Research; Research Personnel; Resources; Science; Services; Structure; Technology; Time; Transcript; anticancer research; programs; response; tool

The Biochemistry and Biotechnology Facility (BBF) makes available to Fox Chase Cancer Center (FCCC) investigators a group of state-of-the-art technologies for the identification, characterization, and utilization of genes, polymorphisms, transcripts, proteins; and peptides. The four components of BBF are all important and synergistic. DMA Synthesis delivers error-free oligonucleotides, regular, modified, or fluorescent probes, overnight with full quality control, Quantitative Real-time PCR provides high sensitivity and accuracy gene expression quantitation and distinguishes regulation by alternate transcripts. Mass Spectrometry identifies the components of protein complexes and supports biochemical, biophysical, and drug research. Proteomics reveals the global protein changes and modifications in response to disease states or drug treatments and discovers secondary targets of cancer-causing mutations. Anthony T. Yeung, Ph.D., (Biomolecular Structure and Function) directs BBF to provide uniformly high quality products at the cutting edge of performance. This is accomplished by proactive user interactions, and external collaborations with the leaders in each discipline. The Facility is used by 53 peer-reviewed investigators with 130 grants involving all three FCCC Divisions. About 95% of its use is by investigators with peer-reviewed funding. During the last grant period, demands on DNA synthesis (700 oligonucleotides per month by 2003) and Mass Spectrometry (about 22 projects in 2003) have both doubled. In addition, new services of Quantitative Real-time PCR and Proteomics have been developed in BBF because they are critical technologies for cancer research and are used by 13 and 7 investigators, respectively. In 2003, DNA Synthesis has contributed to 48 peer-reviewed, funded investigators, Quantitative Real-time PCR, 14; Mass Spectrometry, 23; and Proteomics, 7. BBF personnel have in-depth understanding of the science of the users and facilitate their research as highly integrated tools and participants of these research programs.

生物化学和生物技术设施（BBF）提供福克斯蔡斯癌症